ArticleAMB Express2025
Mastoparan-S from Sphodromantis viridis exhibits antimicrobial activity by disrupting bacterial membranes.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increasing prevalence of antimicrobial resistance underscores the urgent need for alternative treatments. Antimicrobial peptides (AMPs) are considered viable substitutes for conventional antibiotics due to their broad-spectrum activity and unique mechanisms of action. AMPs are an integral component of the innate immune system in invertebrates. Mastoparan-S, a 14-amino acid AMP originally identified in the praying mantis Sphodromantis viridis reportedly exhibits antimicrobial activity against gram-positive and gram-negative bacteria, as well as fungi. In this study, the antibacterial activity and mechanism of action of chemically-synthesized mastoparan-S are evaluated against Staphylococcus aureus and Pseudomonas aeruginosa. Mastoparan-S exhibits potent antibacterial activity against S. aureus and P. aeruginosa, without inducing cytotoxicity or hemolytic activity in RAW264.7 or HaCaT cells. Mastoparan-S effectively inhibits biofilm formation by S. aureus and P. aeruginosa. Mechanistically, mastopran-S kills bacteria by disrupting the bacterial membrane. Collectively, these findings suggest that mastoparan-S is a potential therapeutic agent for treating S. aureus and P. aeruginosa infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.